2. 您的位置
3. 首页
4. 会议论文
5. Molecular mechanism of regulation of extramedullary infiltration by APP gene in AML1/ETO positive ac

Molecular mechanism of regulation of extramedullary infiltration by APP gene in AML1/ETO positive ac

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户：z3753091

【摘 要】

：

Amyloid precusor protein (APP) has been reported to be highly expressed in AML1/ETO positive acute myeloid leukemia (AML1/ETO+ AML),and we found it express even higher in those with extramedullary inf

【作 者】

：

guopan yu ling jiangl fanyi meng changxin Yin zhixiang wang hongsheng zhou xuejie jiang lingxiu zhang rui cao libin liao 

【机 构】

：

Department of Hematology,Nanfang Hospital,Southern Medical University

【出 处】

：

The 35th World Congress of the International Society of Hema

【发表日期】

：

2014年5期

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Amyloid precusor protein (APP) has been reported to be highly expressed in AML1/ETO positive acute myeloid leukemia (AML1/ETO+ AML),and we found it express even higher in those with extramedullary infiltration in our previous study.Yet,its still unknown what role APP plays and how it works in AML1/ETO+ AML.

其他文献

Long term follow up of Chronic Myeloid Leukaemia patients on tyrosine kinase inhibitors in Penang, M

Objective Tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of Chronic myeloid leukaemia (CML) worldwide.Community-based data would be more reflective of the actual outcome a

会议

Clinical Outcome and Survival in Chronic Myeloid Leukaemia Patients on Second Line Nilotinib Therapy

Objective The introduction of tyrosine kinase inhibitors (TKI) has changed the evolution and prognosis of Chronic Myeloid Leukaemia (CML) worldwide.However,the cost of TKIs is exorbitant and sometimes

会议

Clinical significance of chromosome abnormalities in patients with chronic myelogenous leukemia in r

Similar to additional cytogenetic aberrations in patients with newly diagnosed chronic myelogenous leukemia-chronic phase (CML-CP),the clinical significance of chromosome abnormalities in patients wit

会议

A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtyp

Objective To explore the clinical and laboratory features of chronic myeloid leukemia (CML) with atypical e14a3 and e19a2 BCR-ABL fusion gene subtypes.Methods We retrospectively analyzed a cohort of C

会议

Emodin induces growth inhibition and downregulation of Akt signaling pathway in acute myeloid leukem

Objective The effects of emodin on growth inhibition and Akt pathway regulation were investigated in acute myeloid leukemia (AML) cells and AML xenograft models.Methods (1) Cell proliferation was meas

会议

The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of

Objective The purpose of the current study was to illustrate the specific constitution and immune regulation mechanisms of Th subsets (especially the novel recognized Th17/Treg,Th9 and Th22 subsets) i

会议

Citrate, as a glucolysis inhibitor for the treatment of acute leukemia, inhibits PFK and HIF-1α sign

Objective This study aims to investigate the anti-glucolysis activities of citrate and its underlying mechanism in acute leukemia (AL).Methods The cytotoxities of citrate against cancer cells were det

会议

The chromosome open reading frame genes targeted by abnormal miRNAs in microvesicles from non-solid

Object Chronic myeloid leukemia (CML),a kind of non-solid tumor,is characterized by BCR-ABL1 fusion gene.Hepatocellular carcinoma (HCC) is one of the most common solid tumors.Microvesicles (MVs) are s

会议

A preliminary investigation screening of serum protein markers by protein microarray technology in a

Method (1)According to cytogenetic marker、genetic test and clinical therapeutic efficacy,totally 113 patients with newly diagnosed AML(non-APL) hospitalised in our department from august 2011 to Janua

会议

Successful treatment of sorafenib-related thyroiditis in a patient with FMS-like tyrosine kinase-3 p

Objective Sorafenib is a novel orally available inhibitor of multiple kinases.It has been used in relapsed and refractory FMS-like tyrosine kinase (FLT)-3 positive AML in recent years with favorable o

会议